Intra-Operative 3D Surgical Navigation System has FDA clearance.
Press Release Summary:
Featuring FDA clearance, IQQAÂ®-Guide supports intra-operative precision 3D navigation for surgical procedures of thoracic, abdominal, and pelvic soft-organs. Fully quantified and patient-specific IQQAÂ® anatomic models, extracted from multi-modality images, are utilized for on-the-fly 3D navigation to support physicians in seeing through organ surfaces and quantitatively referencing anatomies of interest during surgery. Platform covers pre-operative planning, intra-operative navigation and monitoring,Â as well asÂ post-operative assessment.
Original Press Release:
EDDA Technology Introduces the Newly FDA-Cleared IQQA®-Guide Intra-operative Precision 3D Navigation for Minimally Invasive and Robotic Surgical Treatment
PRINCETON, N.J. -- EDDA Technology, a global leading provider in advanced imaging-guided precision treatment solutions, announced today that the company has received FDA clearance on IQQA(®)-Guide, a system that supports intra-operative precision 3D navigation for surgical procedures of thoracic, abdominal, and pelvic soft-organs.
IQQA(®)-Guide is the latest addition to the IQQA(®) Platform and Product Suite. It expands the award-winning IQQA(®) precision 3D imaging analytics into the operating room. Fully quantified and patient-specific IQQA(®) anatomic models are extracted from multi-modality images, and utilized for on-the-fly 3D navigation to support physicians in "seeing through" organ surfaces and quantitatively referencing anatomies of interest in 3D during surgery. Clinical studies (WICO 2015) suggest that IQQA(®)-Guide may help reduce the use of intra-operative CT scans during imaging-guided surgical procedures.
The treatment planning and follow-up assessment features provided by IQQA(®) -BodyImaging, a part of the IQQA(®) Platform, have already been widely used for liver, kidney, and lung cancers. IQQA(®) -BodyImaging has been proven to provide significant time-saving and improved patient care in more than 22,000 cases.
"With the latest FDA clearance, the IQQA(®) Platform now covers pre-operative planning, intra-operative navigation and monitoring, and post-operative assessment to complete the full cycle of imaging-guided precision treatment," said Dr. Jianzhong Qian, President and CEO of EDDA Technology. "Powered by our precision 3D capabilities, IQQA(®)-Guide may help facilitate the next generation of minimally invasive and robotic treatments in precision medicine".
EDDA will exhibit its IQQA(®) Platform and Product Suite as well as cloud-based service in Booth #8127 at RSNA 2015.
About EDDA Technology
EDDA Technology, Inc. is an innovative clinical solution provider in the rapidly growing field of imaging-guided minimally invasive and robotic treatment. Pioneering a "fully quantitative, real-time interactive" approach to multimodality imaging analysis and guidance, EDDA offers a series of next generation computer-assisted solutions for the entire patient management cycle, by enabling early detection and diagnosis, and enhancing efficiency and precision in treatment planning, guidance, monitoring, and follow-up. EDDA's goal is to deliver, with broad accessibility, advanced imaging analytics technology and services that improve clinical workflow and accuracy. EDDA is headquartered in Princeton, New Jersey, and has subsidiaries in Shanghai and Suzhou, China. IQQA(®) is a registered trademark of EDDA Technology. www.eddatech.com
CONTACT: Zeng Xiaolan, 609-919-9889 ext 106, email@example.com